Nebula Research & Development LLC Acquires 5,206 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Nebula Research & Development LLC grew its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 159.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,469 shares of the medical instruments supplier's stock after acquiring an additional 5,206 shares during the period. Nebula Research & Development LLC's holdings in LeMaitre Vascular were worth $780,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its position in LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 293 shares during the last quarter. CBIZ Investment Advisory Services LLC increased its stake in LeMaitre Vascular by 38.5% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 117 shares during the last quarter. KBC Group NV increased its stake in LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after acquiring an additional 410 shares during the last quarter. Huntington National Bank increased its stake in LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after acquiring an additional 455 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in LeMaitre Vascular in the fourth quarter valued at approximately $150,000. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Down 2.0 %

LMAT stock traded down $1.86 during midday trading on Wednesday, hitting $90.74. The company's stock had a trading volume of 163,501 shares, compared to its average volume of 161,726. The stock's 50-day moving average price is $86.50 and its 200 day moving average price is $93.45. LeMaitre Vascular, Inc. has a 1 year low of $64.80 and a 1 year high of $109.58. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 49.58, a PEG ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were paid a $0.20 dividend. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. This represents a $0.80 annualized dividend and a dividend yield of 0.88%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 41.24%.

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.79% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LMAT. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Wells Fargo & Company began coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price for the company. Lake Street Capital lifted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Finally, Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of "Moderate Buy" and an average target price of $98.14.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.